Exelixis (EXEL) Q2 FY26 earnings call

Exelixis is executing its strategy to transition from a single-compound company to a multi-franchise oncology business, driven by the expanding zanzalintinib pipeline and continued growth of the cabozantinib franchise. While the company adjusted its full-year revenue outlook due to a more gradual ramp in the NET indication, it remains committed to disciplined capital allocation and advancing its broad clinical development program for zanzalintinib across multiple tumor types.